In its legal battle with much-larger St. Jude Medical, medical device company AccessClosure will walk away with a concession prize: They escape the threat of an injunction over their vascular puncture technology.
St. Jude Medical may have snagged a CE mark for its next-gen EnligHTN IV renal denervation system, but a U.S. clinical trial for the device has come to a screeching halt. That means Medtronic is poised to take a bigger lead as a result.
St. Jude Medical has begun enrolling patients in a clinical trial to test whether combining peripheral nerve field stimulation and spinal cord stimulation to manage chronic low back and leg pain is more effective than spinal cord stimulation alone.
Seeking to remain ahead of the pack of medical device companies focused on developing neurostimulation devices to treat chronic pain and other conditions, St. Jude Medical has launched a clinical trial of a next-generation device that ups the ante for rivals.
St. Jude Medical is celebrating promising early international data from its Portico transcatheter aortic heart valve, showing that most patients with the implant experienced major benefits after a month.
St. Jude Medical got sideswiped with an FDA safety alert over one of the company's heart plugs based on reports that it could potentially wear away tissue and, ironically, create more holes.
St. Jude Medical has been shedding jobs and cutting costs over the past year, and the prolonged restructuring is paying off on the balance sheet: The Minnesota devicemaker boosted its net income by more than 40% in the third quarter despite a middling increase in revenue.
St. Jude Medical snatched up Nanostim for at least $123.5 million, giving it bragging rights as the owner of the only leadless cardiac pacemaker to hit the market so far.
St. Jude Medical CEO Daniel Starks gives infrequent interviews and only sporadically speaks in public. He had a lot to say, however, at the Minnesota Venture Finance Conference Thursday, where he sounded off, in part, against an unnamed rival's growth strategy.
CardioMEMS and investor St. Jude Medical have a lot riding on the Champion heart failure device, and the pair picked up a split vote from an FDA panel, with members divided on whether the diagnostic system is effective enough to merit approval.